°¡Å縯´ëÇб³¼¿ï¼º¸ðº´¿ø CMC Á¾¾ç³»°ú ½ÉÆ÷Áö¾ö(Æó¾Ï/µÎ°æºÎ¾Ï) : 2019-02-15±³À°ÀÏÀÚ : 2019-02-15
±³À°Àå¼Ò : ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
CMC Á¾¾ç³»°ú ½ÉÆ÷Áö¾ö(Æó¾Ï/µÎ°æºÎ¾Ï)ÁÖÃÖ±â°ü : °¡Å縯´ëÇб³¼¿ï¼º¸ðº´¿ø
´ã´çÀÚ : Àü»óÈÆ
¿¬¶ôó : 032-340-2012
À̸ÞÀÏ :
rowett@naver.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 13:30~14:00 Re-irradiation strategy in recurrent or secondary head and neck cancer ¼º¼öÀ±(¼¿ï¼º¸ðº´¿ø ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 14:00~14:30 Role of surgery and rehabilitation for locally advanced laryngeal cancer Á¶Á¤ÇØ(¼ººó¼¾Æ®º´¿ø À̺ñÀÎÈÄ°ú)
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 14:30~15:00 New systemic treatment option in head and neck cancer ¾ÈÈ£Á¤(¼ººó¼¾Æ®º´¿ø Á¾¾ç³»°ú)
ÈÞ½Ä 02-15 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 15:20~15:50 Recent update in immuno oncology from bench to clinic È«ÁöÇü(ÀÎõ¼º¸ðº´¿ø Á¾¾ç³»°ú)
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 15:50~16:20 Review in management of EGFR mutant NSCLC other than 3rd gen EGFR TKI Àü»óÈÆ(ºÎõ¼º¸ðº´¿ø Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 02-15 ¼ºÀDZ³Á¤ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 16:20~16:50 The era of New ALK inhibitor È«¼÷Èñ(¼¿ï¼º¸ðº´¿ø Á¾¾ç³»°ú)